Macquarie Group’s Adicet Bio ACET Stock Holding History

Macquarie Group’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-168	Closed	-$3.26K	–	1654
2024 Q2	$3.26K	Buy	+168	New	+$4.5K	﹤0.01%	1757

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Macquarie Group's ACET Position: Q3 2024 in Review

Macquarie Group sold out of Adicet Bio (ACET) in Q3 2024, closing a stake of 168 shares — an estimated $3.26K sold.

Macquarie Group first reported a position in ACET in Q2 2024 and held it in 1 quarter. The position peaked at $3.26K in Q2 2024. 64 funds tracked by Wall St. Rank hold ACET as of Q3 2024.

Macquarie Group reported no remaining Adicet Bio position as of Q3 2024 after selling out during the quarter.
Macquarie Group sold 168 Adicet Bio shares in Q3 2024, an estimated $3.26K.
Macquarie Group first reported a position in Adicet Bio in Q2 2024 and held it in 1 quarter.
Macquarie Group's Adicet Bio position peaked at $3.26K in Q2 2024.
64 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2024.

Based on Macquarie Group's 13F filing for Q3 2024, filed 14 Nov 2024.